The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
BGI will study pancreatic cancer with a group at Johns Hopkins and develop a diagnostic test for preterm birth detection with Mount Sinai Hospital researchers.
Based on genome data for 3,010 Asian rice accessions, researchers retraced the domestication history and diversity of Xian/Indica and Geng/Japonica rice.
This week's news includes Danaher, BGI, Mobadiag, and Sygnis.
The partners plan to share information about joint R&D activities and establish research facilities and laboratory infrastructure in Ethiopia.
In a study published in PLOS One last month, the researchers compared results from the BGISEQ-500 and the Illumina HiSeq X Ten for tumor and germline samples from three patients.
BGI has ordered 10 Sequel systems to meet long-read sequencing demand for bacterial, plant, and animal de novo, transcriptome, and epigenomics sequencing.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.